BR112022010879A2 - Métodos e composições para tratamento de edema refratário a diuréticos orais - Google Patents
Métodos e composições para tratamento de edema refratário a diuréticos oraisInfo
- Publication number
- BR112022010879A2 BR112022010879A2 BR112022010879A BR112022010879A BR112022010879A2 BR 112022010879 A2 BR112022010879 A2 BR 112022010879A2 BR 112022010879 A BR112022010879 A BR 112022010879A BR 112022010879 A BR112022010879 A BR 112022010879A BR 112022010879 A2 BR112022010879 A2 BR 112022010879A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- treatment
- methods
- oral diuretics
- edema
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943638P | 2019-12-04 | 2019-12-04 | |
| PCT/US2020/063491 WO2021113775A1 (en) | 2019-12-04 | 2020-12-04 | Methods and compositions for treating edema refractory to oral diuretics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010879A2 true BR112022010879A2 (pt) | 2022-10-18 |
Family
ID=76209409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010879A BR112022010879A2 (pt) | 2019-12-04 | 2020-12-04 | Métodos e composições para tratamento de edema refratário a diuréticos orais |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11123319B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4069222A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7885121B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220113436A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115023223A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020397176A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112022010879A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3160278A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL293429A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021113775A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3160278A1 (en) | 2019-12-04 | 2021-06-10 | Balasingam Radhakrishnan | Methods and compositions for treating edema refractory to oral diuretics |
| JP2024520788A (ja) * | 2021-06-09 | 2024-05-24 | レスク ファーマシューティカルズ エルエルシー | 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 |
| JP2024526357A (ja) * | 2021-07-16 | 2024-07-17 | ドリペル ビー．ブイ． | 水性ブメタニド含有液体 |
| IL313921A (en) * | 2021-12-30 | 2024-08-01 | Neuropro Therapeutics Inc | Pharmaceutical composition |
| CN115645363B (zh) * | 2022-10-31 | 2025-06-10 | 浙江普利药业有限公司 | 一种布美他尼注射液及其制备方法 |
| WO2026017600A1 (en) | 2024-07-15 | 2026-01-22 | Dripel B.V. | Aqueous bumetanide-containing liquid |
| WO2026043819A1 (en) * | 2024-08-19 | 2026-02-26 | Strategic Drug Solutions, Inc. | Formulations and methods for convenient and rapid diuresis for the treatment of edema |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| EP2389371A4 (en) * | 2009-01-22 | 2012-09-12 | Neurotherapeutics Pharma Inc | ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE |
| JP5914357B2 (ja) * | 2010-01-15 | 2016-05-11 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 自閉症の治療のための化合物 |
| AU2012250050B2 (en) * | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| US20140128469A1 (en) * | 2011-05-10 | 2014-05-08 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
| US20150239832A1 (en) * | 2012-09-04 | 2015-08-27 | Neuro Pro Therapeutics, Inc. | Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use |
| KR20160091348A (ko) * | 2014-06-08 | 2016-08-02 | 오토텔릭 엘엘씨 | 부종없이 통증을 완화시키기 위한 고정된 용량의 복합제 |
| WO2019193161A1 (en) * | 2018-04-06 | 2019-10-10 | Universität Wien | Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs |
| CA3160278A1 (en) | 2019-12-04 | 2021-06-10 | Balasingam Radhakrishnan | Methods and compositions for treating edema refractory to oral diuretics |
| JP2024520788A (ja) | 2021-06-09 | 2024-05-24 | レスク ファーマシューティカルズ エルエルシー | 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 |
-
2020
- 2020-12-04 CA CA3160278A patent/CA3160278A1/en active Pending
- 2020-12-04 KR KR1020227022652A patent/KR20220113436A/ko active Pending
- 2020-12-04 WO PCT/US2020/063491 patent/WO2021113775A1/en not_active Ceased
- 2020-12-04 US US17/112,899 patent/US11123319B2/en active Active
- 2020-12-04 AU AU2020397176A patent/AU2020397176A1/en active Pending
- 2020-12-04 IL IL293429A patent/IL293429A/en unknown
- 2020-12-04 CN CN202080090912.6A patent/CN115023223A/zh active Pending
- 2020-12-04 JP JP2022533344A patent/JP7885121B2/ja active Active
- 2020-12-04 EP EP20896035.1A patent/EP4069222A4/en active Pending
- 2020-12-04 BR BR112022010879A patent/BR112022010879A2/pt unknown
-
2021
- 2021-06-11 US US17/345,550 patent/US11260038B1/en active Active
-
2022
- 2022-02-25 US US17/680,591 patent/US12150923B2/en active Active
-
2024
- 2024-10-15 US US18/916,471 patent/US12329731B2/en active Active
-
2025
- 2025-05-14 US US19/208,335 patent/US12558330B2/en active Active
- 2025-12-25 JP JP2025281644A patent/JP2026076167A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12150923B2 (en) | 2024-11-26 |
| WO2021113775A1 (en) | 2021-06-10 |
| AU2020397176A1 (en) | 2022-06-30 |
| JP7885121B2 (ja) | 2026-07-06 |
| CA3160278A1 (en) | 2021-06-10 |
| CN115023223A (zh) | 2022-09-06 |
| US20210169833A1 (en) | 2021-06-10 |
| US11260038B1 (en) | 2022-03-01 |
| US20220287996A1 (en) | 2022-09-15 |
| US20250268853A1 (en) | 2025-08-28 |
| KR20220113436A (ko) | 2022-08-12 |
| US20250032436A1 (en) | 2025-01-30 |
| IL293429A (en) | 2022-07-01 |
| US12329731B2 (en) | 2025-06-17 |
| WO2021113775A8 (en) | 2021-07-22 |
| US11123319B2 (en) | 2021-09-21 |
| EP4069222A1 (en) | 2022-10-12 |
| EP4069222A4 (en) | 2023-12-27 |
| JP2026076167A (ja) | 2026-05-11 |
| US12558330B2 (en) | 2026-02-24 |
| JP2023505189A (ja) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190983A1 (ru) | Новое антитело к с-kit | |
| BR112022008294A2 (pt) | Composições de profármaco e métodos de tratamento | |
| WO2021113775A8 (en) | Methods and compositions for treating edema refractory to oral diuretics | |
| MX2023009561A (es) | Moduladores de profarmacos de la via de estres integrada. | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| ECSP20024210A (es) | Uso de inhibidores de p38 para reducir la expresión de dux4 | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
| MX376201B (es) | Compuestos inhibidores de metaloenzima. | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| BR112018000786A2 (pt) | métodos e composições usando bifidobacterium longum para modular a reatividade emocional e tratar ou evitar perturbações subclínicas do estado de humor | |
| UA124939C2 (uk) | СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ | |
| PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
| EA201892051A1 (ru) | Фармацевтические композиции для лечения злокачественного новообразования | |
| BR112021023144A2 (pt) | Compostos de oxatiazina para inibir gapdh | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| MX2020012065A (es) | Compuestos de ciclopentano. | |
| PH12020551331A1 (en) | Treatment and prevention of pre-eclampsia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122026013552-9 PROTOCOLO 870260052988 EM 01/06/2026 16:41.O PEDIDO FOI DIVIDIDO NO BR122026013552-9 PROTOCOLO 870260052988 EM 01/06/2026 16:41. |